<--GAT-->
Clinical Topics

Incidence of NK/T-cell Lymphoma Rises Significantly in the United States

by U.S. Medicine

August 19, 2018

COLUMBIA, SC—Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer/T-cell neoplasms in the United States.

A new study conducted to remedy that lack of information reported in Clinical Lymphoma, Myeloma & Leukemia that rates were rising significantly.1

A study team led by the University of South Carolina School of Medicine and including participation from the VA Nebraska Western Iowa Health Care System performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The researchers estimated the overall survival difference among the subgroups and analyzed the data to determine the factors affecting survival.

They found that, for the 797 patients with NK/T-cell lymphoma, nasal type, the median age at diagnosis was 53 years, and males tended to be younger at diagnosis (P< .0001).

What was surprising was how much diagnosis of the disease had increased, study authors said pointing out that incidence increased from 0.4 in 2001 to 0.8 in 2014 per 1,000,000 individuals, with incidence significantly greater in Hispanic patients compared with that in non-Hispanic patients (rate ratio, 3.03; P= .0001).

The median overall survival, meanwhile, was 20 months (range, 2-73 months) and varied significantly according to the primary site (P< .0001) and the disease stage at diagnosis (P< .0001). NK/T-cell lymphoma patients also had an increased risk of acute myeloid leukemia (standardized incidence ratio, 18.77; 95% confidence interval, 2.27-67.81), the study said.

Specifically for the 105 NK/T-cell leukemia patients, the median age at diagnosis was 58 years (range, 4-95 years), and the overall incidence of the disease was 0.09 per 1,000,000 individuals, although significantly greater in males (rate ratio, 0.41; P< .0001). Unlike NK/T-cell lymphoma, no racial disparities were found in the incidence, researchers pointed out, adding that the median overall survival was 17 months (range, 0-36 months).

“The incidence of NK/T-cell lymphoma, nasal type, in the United States has at least doubled in the past decade, with the greatest predilection among Hispanics,” study authors concluded. “Patients with NK/T-cell lymphoma might have an increased risk of the subsequent development of acute myeloid leukemia.”

1. Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):475-479. doi: 10.1016/j.clml.2018.04.009. Epub 2018 May 4. PubMed PMID: 29752210.


Comments are closed here.


Related Articles

‘Severe’ 2017-18 Influenza Season Hit VA Especially Hard

This likely will come as little surprise to healthcare professionals who soldiered through it, but the 2017-18 influenza season was the most severe since VA surveillance was initiated in 2009.

VA Examines Ways to Lessen Care Disruption During EHR Implementation

Clinician input will play an important part in decisions that need to be made regarding VA's new EHR, VA officials assured lawmakers last month.


U.S. Medicine Recommends


More From oncology

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Oncology

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up